Roche joins the M&A game, buying gene therapy pioneer Spark for $4.3B
It’s official. Roche is joining the multibillion-dollar M&A game, acquiring a top player in the booming gene therapy business.
Image: Spark CEO Jeffrey Marrazzo at an Endpoints News panel during the 2019 JP Morgan conference Jeff Rumans for Endpoints News
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.